Lv3
336 积分 2026-01-21 加入
Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma
2个月前
已完结
Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma
2个月前
已完结
Therapeutic potentials of Apatinib in cancer treatment: Possible mechanisms and clinical relevance
2个月前
已完结
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
2个月前
已完结
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
2个月前
已完结
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
2个月前
已完结
Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
2个月前
已完结
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
2个月前
已完结
Donafenib: First Approval
2个月前
已完结
Lenvatinib: A Review in Hepatocellular Carcinoma
2个月前
已完结
皖公网安备34019202002308
